z-logo
open-access-imgOpen Access
Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi
Author(s) -
Susan J. Robertson,
Lisa Orme,
Rodrigo Teixeira,
Maryam Shamassi,
Felicity Newell,
AnnMarie Patch,
Iwei Yeh,
Grace Gard,
James S. Wilmott,
Louise Jackett,
Philip E. LeBoit,
Andrew Fellowes,
Grant MacArthur,
Stephen B. Fox,
Nicholas K. Hayward,
Boris C. Bastian,
Richard A. Scolyer,
Nicola Waddell,
Anthony Penington,
Mark Shackleton
Publication year - 2021
Publication title -
jama dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.128
H-Index - 166
eISSN - 2168-6084
pISSN - 2168-6068
DOI - 10.1001/jamadermatol.2021.0025
Subject(s) - crizotinib , medicine , spitz nevus , ros1 , dermatology , nevus , melanoma , pathology , cancer research , cancer , adenocarcinoma , malignant pleural effusion , lung cancer
Spitz nevi are benign melanocytic neoplasms that classically present in childhood. Isolated Spitz nevi have been associated with oncogenic gene fusions in approximately 50% of cases. The rare agminated variant of Spitz nevi, thought to arise from cutaneous genetic mosaicism, is characterized by development of clusters of multiple lesions in a segmental distribution, which can complicate surgical removal. Somatic single-nucleotide variants in the HRAS oncogene have been described in agminated Spitz nevi, most of which were associated with an underlying nevus spilus. The use of targeted medical therapy for agminated Spitz nevi is not well understood.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom